Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.